Scarica l'app Stockscreener
3.56
0.00%
0.00
Pre-mercato:
3.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.56
Aprire:
$3.6
Volume 24 ore:
255.47K
Relative Volume:
0.39
Capitalizzazione di mercato:
$136.70M
Reddito:
$114.20M
Utile/perdita netta:
$-3.08M
Rapporto P/E:
-9.1634
EPS:
-0.3885
Flusso di cassa netto:
$-77.20M
1 W Prestazione:
-5.32%
1M Prestazione:
+10.22%
6M Prestazione:
-8.72%
1 anno Prestazione:
+113.17%
Intervallo 1D:
$3.535
$3.68
Intervallo di 1 settimana:
$3.505
$3.87
Portata 52W:
$1.38
$7.34
Agenus Inc Stock (AGEN) Company Profile
Nome
Agenus Inc
Settore
Industria
Telefono
781-674-4410
Indirizzo
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.56 | 136.70M | 114.20M | -3.08M | -77.20M | -0.3885 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Iniziato | Robert W. Baird | Outperform |
| 2023-02-28 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-28 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-19 | Ripresa | B. Riley FBR | Buy |
| 2019-04-22 | Iniziato | B. Riley FBR | Buy |
| 2016-10-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Reiterato | Maxim Group | Buy |
| 2016-03-11 | Aggiornamento | Maxim Group | Hold → Buy |
| 2015-12-16 | Iniziato | Jefferies | Buy |
| 2015-10-27 | Downgrade | Maxim Group | Buy → Hold |
| 2015-07-27 | Reiterato | MLV & Co | Buy |
| 2015-06-11 | Iniziato | Oppenheimer | Outperform |
| 2015-01-12 | Reiterato | Maxim Group | Buy |
| 2015-01-09 | Reiterato | MLV & Co | Buy |
| 2015-01-09 | Reiterato | Maxim Group | Buy |
| 2014-12-19 | Reiterato | Maxim Group | Buy |
| 2014-05-08 | Reiterato | Maxim Group | Buy |
| 2014-03-14 | Reiterato | MLV & Co | Buy |
| 2013-10-08 | Reiterato | Maxim Group | Buy |
| 2012-01-05 | Iniziato | William Blair | Outperform |
| 2011-12-01 | Iniziato | Global Hunter Securities | Buy |
Mostra tutto
Agenus Inc Borsa (AGEN) Ultime notizie
Agenus Secures Dismissal of Investors’ Cancer Drug Class Action - Bloomberg Law News
Agenus (AGEN) presents new phase 1b clinical data on BOT/BAL combination for MSS mCRC - MSN
Agenus Escapes Investor Fraud Suit Over Cancer Drug - Law360
Agenus (NASDAQ: AGEN) director Armen paid salary in stock grant - Stock Titan
Agenus Q4 2025 earnings preview - MSN
AGEN Technical Analysis | Trend, Signals & Chart Patterns | AGENUS INC (NASDAQ:AGEN) - ChartMill
Agenus (NASDAQ:AGEN) Rating Increased to Buy at Wall Street Zen - MarketBeat
Agenus receives $20M payment under Zydus Life Sciences collaboration - MSN
MiNK Therapeutics (NASDAQ: INKT) names new financial leadership team - Stock Titan
Research Analysts Issue Forecasts for Agenus Q1 Earnings - MarketBeat
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer - BioSpace
Agenus Reports 2025 Financial Results, Advances BOT+BAL to Phase 3 with Expanding Global Access - Oncodaily
Price Action: Will Agenus Inc benefit from rate cuts2026 Setups & Verified Trade Idea Suggestions - baoquankhu1.vn
Agenus stock price target reaffirmed at $8 by B.Riley on revenue growth - Investing.com
Agenus reinforces commitment to global access as new innovation advances - Traders Union
Agenus reports $4.2M in early access revenue for cancer therapy - Investing.com Canada
Agenus Inc. 2025 Annual Report: Immuno-Oncology Strategy, Lead Programs, and Recent Developments - Minichart
Agenus reports $4.2M in early access revenue for cancer therapy By Investing.com - Investing.com South Africa
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Agenus: Fourth Quarter Financial Results Overview - Bitget
Agenus: Q4 Earnings Snapshot - Barchart.com
Agenus Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Agenus Inc. (AGEN) Releases Q4 2025 Earnings: Revenue Up but Wider Net Loss, Cash Plunges - Quiver Quantitative
Agenus 2025 10-K: $114.2M Revenue, $(0.00) EPS - TradingView
Agenus (NASDAQ: AGEN) leans on cancer lead BOT/BAL amid cash risk - Stock Titan
Agenus Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Agenus Reports 2025 Progress: BOT+BAL Immunotherapy Advances to Phase 3 with Global Early Access Programs - Oncodaily
Market Fear: Why is Agenus Inc stock going down2026 Dividend Review & Trade Opportunity Analysis Reports - baoquankhu1.vn
(AGEN.O) | Stock Price & Latest News - Reuters
Form 8K Agenus Inc For: 16 March - Investing.com
Agenus (AGEN) secures Zydus funding as BOT+BAL enters global Phase 3 - Stock Titan
Agenus posts 42 percent 2 year OS and $4.2 million initial revenue on BOT plus BAL programs - Traders Union
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized - Business Wire
Earnings Scheduled For March 16, 2026 - Benzinga
Agenus Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Volume Summary: Should I invest in Agenus Inc before earningsMarket Performance Report & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Agenus to Announce Q4 Earnings on March 16 - Intellectia AI
Agenus Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView
Immuno-oncology initiatives expand to address unmet cancer needs, Agenus asserts - Traders Union
Agenus receives $20M payment from Zydus collaboration By Investing.com - Investing.com Canada
Agenus receives $20M payment from Zydus collaboration - Investing.com Nigeria
Agenus (AGEN) Secures $20M Milestone Payment from Zydus Partners - GuruFocus
Agenus Triggers First $20 Million Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs - marketscreener.com
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs - Business Wire
Agenus (AGEN) director Garo Armen takes 4,994 shares as stock salary - Stock Titan
Agenus warns most metastatic colorectal cancer cases are MSS, calling for innovation to tackle resistance - Traders Union
Agenus Inc Azioni (AGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):